AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 222 min read$LABT

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics (LABT) reported Q2 2026 progress, including Nasdaq listing, $7.5M private placement, and Nu-3 Gel Phase 2a trial prep. The company expanded its IP portfolio and appointed David G. Armstrong as Study Chair. LABT aims to advance Nu-3 for infected diabetic foot ulcers, with clinical trial initiation expected soon.

Original reporting
insidermonkey.com
Published Sep 22, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 4:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$LABTBullishMed
01

Why it matters

The combined corporate financing and scientific progress reduce near‑term execution risk and could attract further investment, supporting a short‑term price rally.

02

Market read

First‑time disclosure of listing, financing, and preclinical data makes the article highly relevant for traders tracking micro‑cap biotech catalysts.

03

What to watch

Potential dilution from convertible preferred conversion and upcoming regulatory hurdles.

Relevance 6/10Novelty 7/10Timing: post‑listing 2026

Background

Lakewood-Amedex Biotherapeutics recently completed a Nasdaq Capital Market listing and raised $7.5M via a private placement, while reporting encouraging preclinical data for its Nu-3 gel candidate targeting infected diabetic foot ulcers.

Company-level read

Ticker impact

$LABTBullishHigh confidence
Context

Lakewood-Amedex Biotherapeutics announced its Nasdaq listing and a $7.5M private placement, plus positive preclinical safety data for Nu-3.

Expected impact

Potential modest price appreciation as investors price in stronger liquidity and reduced clinical risk.

Evidence & confidence

Listing and fresh funding are concrete, material events for a micro‑cap biotech; preclinical data directly affect trial outlook.

Market effects

Sector

Adds credibility to the antimicrobial biotech niche, may lift peer valuations.

Regional

Positive for US small‑cap biotech segment.

Global

Limited to niche antimicrobial sector.

Counterpoint

What could challenge this read

The $7.5M raise is modest; preclinical data may not translate to clinical success, risk remains high.

Key entities

  • company
    Lakewood-Amedex Biotherapeutics Inc.

    Clinical‑stage biotech advancing the Bisphosphocin® antimicrobial platform.

  • person
    David G. Armstrong, DPM, MD, Ph.D.

    Study Chair and Scientific Advisor for the Nu-3 Phase 2a trial.

Read at source← All news

Related articles

SEP 28
$LABTMedAI 8/10

Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections

Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial for Nu-3, a gel treating mildly infected diabetic foot ulcers. The trial will assess safety, efficacy, and optimal dosage. Results are expected in Q1 2027, with potential Phase 2b advancement if successful. According to the company, Nu-3 aims to reduce antimicrobial resistance by targeting infections locally.

proactiveinvestors.com2 min
SEP 24
$LABTLow

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has dosed the first patient in its Phase 2a clinical trial for Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy of three gel concentrations, with topline data expected in Q1 2027. Nu-3 is part of the company's Bisphosphocin® antimicrobial platform.

prnewswire.com2 min
SEP 21
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and clinical site readiness to start a Phase 2a trial for its lead product, Nu-3, treating infected diabetic foot ulcers. The trial aims to evaluate Nu-3's safety and efficacy, building on positive preclinical data. The company aims to address antibiotic-resistant bacterial strains with its Bisphosphocin® class of antimicrobials.

insidermonkey.com2 min
SEP 18
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and confirmed clinical site readiness to start a Phase 2a trial for Nu-3, a treatment for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy, building on positive preclinical data. The company focuses on addressing antibiotic-resistant bacterial infections with its Bisphosphocin® class of antimicrobials.

morningstar.com1 min